Adaptive Net Debt from 2010 to 2025

ADPT Stock

USD 6.81 0.11 1.59%

Adaptive Biotechnologies Net Debt yearly trend continues to be comparatively stable with very little volatility. Net Debt is likely to outpace its year average in 2025. Net Debt is the total debt of Adaptive Biotechnologies Corp minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2018-12-31

Previous Quarter

166.4 M

Current Value

53.7 M

Quarterly Volatility

130.8 M

Covid

Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive Biotechnologies' main balance sheet or income statement drivers, such as Interest Income of 16.3 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 13.1 M, as well as many indicators such as Price To Sales Ratio of 4.54, Dividend Yield of 0.0 or PTB Ratio of 2.17. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.

Check out the analysis of Adaptive Biotechnologies Correlation against competitors.

Latest Adaptive Biotechnologies' Net Debt Growth Pattern

Below is the plot of the Net Debt of Adaptive Biotechnologies Corp over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Adaptive Biotechnologies' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Adaptive Net Debt Regression Statistics

	Arithmetic Mean	(16,906,277)
	Geometric Mean	71,202,417
	Coefficient Of Variation	(617.95)
	Mean Deviation	79,849,369
	Median	(59,969,000)
	Standard Deviation	104,472,596
	Sample Variance	10914.5T
	Range	283.8M
	R-Value	0.83
	Mean Square Error	3671T
	R-Squared	0.69
	Significance	0.000074
	Slope	18,175,957
	Total Sum of Squares	163717.9T

Adaptive Net Debt History

	2025	198.5 M
	2024	189 M
	2023	164.4 M
	2022	18 M
	2021	-27.3 M
	2020	-15.6 M
	2019	-60 M

Other Fundumenentals of Adaptive Biotechnologies

Net Debt To E B I T D A

Adaptive Biotechnologies Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Net Invested Capital	Long Term Investments	Total Current Assets	Net Working Capital	Intangible Assets	Common Stock	Property Plant Equipment	Capital Stock
Total Assets		0.99	0.98	0.98	0.52	-0.65	0.6	-0.4	0.58	-0.29	0.93	0.93	0.89	-0.92	0.99	0.63	0.97	0.93	-0.75	0.92	0.68	0.93
Total Stockholder Equity	0.99		0.99	0.99	0.54	-0.69	0.64	-0.38	0.6	-0.26	0.92	0.94	0.92	-0.94	1.0	0.63	0.95	0.91	-0.79	0.95	0.73	0.95
Net Tangible Assets	0.98	0.99		0.98	0.62	-0.75	0.72	-0.39	0.66	-0.27	0.9	0.96	0.96	-0.97	0.99	0.58	0.94	0.89	-0.85	0.98	0.79	0.98
Current Deferred Revenue	0.98	0.99	0.98		0.57	-0.73	0.65	-0.41	0.64	-0.29	0.86	0.95	0.93	-0.95	0.99	0.65	0.91	0.85	-0.82	0.96	0.79	0.96
Net Debt	0.52	0.54	0.62	0.57		-0.93	0.82	-0.81	0.93	-0.75	0.49	0.78	0.74	-0.75	0.54	-0.12	0.52	0.46	-0.88	0.73	0.77	0.76
Retained Earnings	-0.65	-0.69	-0.75	-0.73	-0.93		-0.91	0.63	-0.96	0.54	-0.57	-0.86	-0.88	0.84	-0.69	-0.06	-0.61	-0.53	0.97	-0.86	-0.93	-0.87
Accounts Payable	0.6	0.64	0.72	0.65	0.82	-0.91		-0.47	0.91	-0.38	0.61	0.8	0.86	-0.78	0.64	-0.06	0.64	0.57	-0.92	0.83	0.88	0.83
Long Term Debt	-0.4	-0.38	-0.39	-0.41	-0.81	0.63	-0.47		-0.74	0.99	-0.37	-0.61	-0.45	0.56	-0.38	0.12	-0.39	-0.36	0.56	-0.47	-0.42	-0.52
Net Receivables	0.58	0.6	0.66	0.64	0.93	-0.96	0.91	-0.74		-0.67	0.54	0.82	0.8	-0.78	0.6	-0.1	0.58	0.51	-0.91	0.78	0.84	0.8
Good Will	-0.29	-0.26	-0.27	-0.29	-0.75	0.54	-0.38	0.99	-0.67		-0.26	-0.5	-0.32	0.45	-0.26	0.19	-0.28	-0.26	0.45	-0.35	-0.32	-0.4
Short Term Investments	0.93	0.92	0.9	0.86	0.49	-0.57	0.61	-0.37	0.54	-0.26		0.86	0.81	-0.82	0.92	0.4	0.99	1.0	-0.67	0.85	0.53	0.85
Long Term Debt Total	0.93	0.94	0.96	0.95	0.78	-0.86	0.8	-0.61	0.82	-0.5	0.86		0.96	-0.99	0.94	0.41	0.9	0.84	-0.92	0.98	0.83	0.99
Capital Surpluse	0.89	0.92	0.96	0.93	0.74	-0.88	0.86	-0.45	0.8	-0.32	0.81	0.96		-0.96	0.92	0.41	0.85	0.79	-0.95	1.0	0.92	0.99
Total Liab	-0.92	-0.94	-0.97	-0.95	-0.75	0.84	-0.78	0.56	-0.78	0.45	-0.82	-0.99	-0.96		-0.94	-0.49	-0.87	-0.81	0.9	-0.98	-0.83	-0.99
Net Invested Capital	0.99	1.0	0.99	0.99	0.54	-0.69	0.64	-0.38	0.6	-0.26	0.92	0.94	0.92	-0.94		0.63	0.95	0.91	-0.79	0.95	0.73	0.95
Long Term Investments	0.63	0.63	0.58	0.65	-0.12	-0.06	-0.06	0.12	-0.1	0.19	0.4	0.41	0.41	-0.49	0.63		0.46	0.43	-0.19	0.45	0.27	0.43
Total Current Assets	0.97	0.95	0.94	0.91	0.52	-0.61	0.64	-0.39	0.58	-0.28	0.99	0.9	0.85	-0.87	0.95	0.46		0.99	-0.72	0.89	0.6	0.89
Net Working Capital	0.93	0.91	0.89	0.85	0.46	-0.53	0.57	-0.36	0.51	-0.26	1.0	0.84	0.79	-0.81	0.91	0.43	0.99		-0.64	0.83	0.5	0.83
Intangible Assets	-0.75	-0.79	-0.85	-0.82	-0.88	0.97	-0.92	0.56	-0.91	0.45	-0.67	-0.92	-0.95	0.9	-0.79	-0.19	-0.72	-0.64		-0.93	-0.96	-0.94
Common Stock	0.92	0.95	0.98	0.96	0.73	-0.86	0.83	-0.47	0.78	-0.35	0.85	0.98	1.0	-0.98	0.95	0.45	0.89	0.83	-0.93		0.88	1.0
Property Plant Equipment	0.68	0.73	0.79	0.79	0.77	-0.93	0.88	-0.42	0.84	-0.32	0.53	0.83	0.92	-0.83	0.73	0.27	0.6	0.5	-0.96	0.88		0.88
Capital Stock	0.93	0.95	0.98	0.96	0.76	-0.87	0.83	-0.52	0.8	-0.4	0.85	0.99	0.99	-0.99	0.95	0.43	0.89	0.83	-0.94	1.0	0.88

Click cells to compare fundamentals

About Adaptive Biotechnologies Financial Statements

Adaptive Biotechnologies shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may analyze each financial statement separately, they are all interrelated. The changes in Adaptive Biotechnologies' assets and liabilities, for example, are also reflected in the revenues and expenses on on Adaptive Biotechnologies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	189 M	198.5 M
Net Debt To EBITDA	(0.78)	(0.82)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adaptive Net Debt from 2010 to 2025

Latest Adaptive Biotechnologies' Net Debt Growth Pattern

Adaptive Net Debt Regression Statistics

Adaptive Net Debt History

Other Fundumenentals of Adaptive Biotechnologies

Adaptive Biotechnologies Net Debt component correlations

About Adaptive Biotechnologies Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Adaptive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY